Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
Cancer Medicine · 2025
DOI: 10.1002/cam4.70718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Tyler J Kristoff und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Immune Checkpoint Inhibitors, Head and Neck Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCD NIH HHS, NCI NIH HHS, National Institute on Deafness and Other Communication Disorders.
Abstract (Originalsprache)
Background
Statin drugs, frequently used to treat hyperlipidemia, are associated with improved survival outcomes in multiple solid tumor types, including head and neck squamous cell carcinoma (HNSCC). Preclinical studies suggest that manipulation of cholesterol with statins and other agents can enhance the function of multiple components involved in anti‐tumor immune responses. Retrospective studies in other solid tumor types suggest that statin therapy is associated with improved responses to immune checkpoint blockade (ICB), but this has not yet been investigated in HNSCC.
Methods
Pharmacy records were searched for patients with recurrent/metastatic HNSCC treated at our institution with pembrolizumab or nivolumab from 2015 to 2022. Patients who received less than 3 doses of ICB were excluded. Univariate and multivariate analyses were performed to determine the association between statin use and objective response, progression‐free survival (PFS) and overall survival (OS).
Results
A total of 158 patients were included. Statins were significantly associated with objective response; the strongest associations were seen with rosuvastatin and lovastatin. On multivariate analyses, statins were independently associated with objective response but not with PFS or OS.
Conclusions
Statin therapy appears to be an independent predictor of response to ICB in HNSCC. Larger, prospective studies are needed to determine whether specific statin drugs can improve survival outcomes in ICB‐treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.
- Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
- Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Astellas Pharma Global Development Inc, Northbrook, Illinois, USA.
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health of Emory University, Atlanta, Georgia, USA.
- Department of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Nicole C Schmitt
Förderung
- NIDCD NIH HHS
- NCI NIH HHS
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Kristoff, T. J., Evans, S., Nayi, P., Abousaud, M., Goyal, S., Liu, Y., Shin, D., Steuer, C. E., Saba, N. F., & Schmitt, N. C. (2025). Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70718
Vancouver
Kristoff TJ, Evans S, Nayi P, Abousaud M, Goyal S, Liu Y, et al. Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.70718
BibTeX
@article{Kristoff2025,
author = {Kristoff, Tyler J and Evans, Sean and Nayi, Pranay and Abousaud, Marin and Goyal, Subir and Liu, Yuan and Shin, Dong and Steuer, Conor E and Saba, Nabil F and Schmitt, Nicole C},
title = {Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70718}
}
EUVIMED